225 related articles for article (PubMed ID: 34655242)
1. Interplay between cardiolipin and plasmalogens in Barth syndrome.
Bozelli JC; Epand RM
J Inherit Metab Dis; 2022 Jan; 45(1):99-110. PubMed ID: 34655242
[TBL] [Abstract][Full Text] [Related]
2. Promotion of plasmalogen biosynthesis reverse lipid changes in a Barth Syndrome cell model.
Bozelli JC; Lu D; Atilla-Gokcumen GE; Epand RM
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Jun; 1865(6):158677. PubMed ID: 32126285
[TBL] [Abstract][Full Text] [Related]
3. Plasmalogen loss caused by remodeling deficiency in mitochondria.
Kimura T; Kimura AK; Ren M; Monteiro V; Xu Y; Berno B; Schlame M; Epand RM
Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31434794
[TBL] [Abstract][Full Text] [Related]
4. Cardiolipin function in the yeast S. cerevisiae and the lessons learned for Barth syndrome.
Ji J; Greenberg ML
J Inherit Metab Dis; 2022 Jan; 45(1):60-71. PubMed ID: 34626131
[TBL] [Abstract][Full Text] [Related]
5. The lipid environment modulates cardiolipin and phospholipid constitution in wild type and tafazzin-deficient cells.
Oemer G; Koch J; Wohlfarter Y; Lackner K; Gebert REM; Geley S; Zschocke J; Keller MA
J Inherit Metab Dis; 2022 Jan; 45(1):38-50. PubMed ID: 34494285
[TBL] [Abstract][Full Text] [Related]
6. Cardiolipin deficiency leads to the destabilization of mitochondrial magnesium channel MRS2 in Barth syndrome.
Joshi A; Gohil VM
Hum Mol Genet; 2023 Dec; 32(24):3353-3360. PubMed ID: 37721533
[TBL] [Abstract][Full Text] [Related]
7. Long-chain fatty acid oxidation and respiratory complex I deficiencies distinguish Barth Syndrome from idiopathic pediatric cardiomyopathy.
Chatfield KC; Sparagna GC; Specht KS; Whitcomb LA; Omar AK; Miyamoto SD; Wolfe LM; Chicco AJ
J Inherit Metab Dis; 2022 Jan; 45(1):111-124. PubMed ID: 34821394
[TBL] [Abstract][Full Text] [Related]
8. Expression of human monolysocardiolipin acyltransferase-1 improves mitochondrial function in Barth syndrome lymphoblasts.
Mejia EM; Zegallai H; Bouchard ED; Banerji V; Ravandi A; Hatch GM
J Biol Chem; 2018 May; 293(20):7564-7577. PubMed ID: 29563154
[TBL] [Abstract][Full Text] [Related]
9. Cardiolipin remodeling: a regulatory hub for modulating cardiolipin metabolism and function.
Ye C; Shen Z; Greenberg ML
J Bioenerg Biomembr; 2016 Apr; 48(2):113-23. PubMed ID: 25432572
[TBL] [Abstract][Full Text] [Related]
10. Substantial Decrease in Plasmalogen in the Heart Associated with Tafazzin Deficiency.
Kimura T; Kimura AK; Ren M; Berno B; Xu Y; Schlame M; Epand RM
Biochemistry; 2018 Apr; 57(14):2162-2175. PubMed ID: 29557170
[TBL] [Abstract][Full Text] [Related]
11. SS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome.
Russo S; De Rasmo D; Rossi R; Signorile A; Lobasso S
Sci Rep; 2024 Jun; 14(1):13655. PubMed ID: 38871974
[TBL] [Abstract][Full Text] [Related]
12. Cardiolipin Remodeling Defects Impair Mitochondrial Architecture and Function in a Murine Model of Barth Syndrome Cardiomyopathy.
Zhu S; Chen Z; Zhu M; Shen Y; Leon LJ; Chi L; Spinozzi S; Tan C; Gu Y; Nguyen A; Zhou Y; Feng W; Vaz FM; Wang X; Gustafsson AB; Evans SM; Kunfu O; Fang X
Circ Heart Fail; 2021 Jun; 14(6):e008289. PubMed ID: 34129362
[TBL] [Abstract][Full Text] [Related]
13. Decreased pyruvate dehydrogenase activity in Tafazzin-deficient cells is caused by dysregulation of pyruvate dehydrogenase phosphatase 1 (PDP1).
Liang Z; Ralph-Epps T; Schmidtke MW; Kumar V; Greenberg ML
J Biol Chem; 2024 Mar; 300(3):105697. PubMed ID: 38301889
[TBL] [Abstract][Full Text] [Related]
14. Experimental models of Barth syndrome.
Pu WT
J Inherit Metab Dis; 2022 Jan; 45(1):72-81. PubMed ID: 34370877
[TBL] [Abstract][Full Text] [Related]
15. Diverse mitochondrial abnormalities in a new cellular model of TAFFAZZIN deficiency are remediated by cardiolipin-interacting small molecules.
Anzmann AF; Sniezek OL; Pado A; Busa V; Vaz FM; Kreimer SD; DeVine LR; Cole RN; Le A; Kirsch BJ; Claypool SM; Vernon HJ
J Biol Chem; 2021 Sep; 297(3):101005. PubMed ID: 34314685
[TBL] [Abstract][Full Text] [Related]
16. Loss of tafazzin results in decreased myoblast differentiation in C2C12 cells: A myoblast model of Barth syndrome and cardiolipin deficiency.
Lou W; Reynolds CA; Li Y; Liu J; Hüttemann M; Schlame M; Stevenson D; Strathdee D; Greenberg ML
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Aug; 1863(8):857-865. PubMed ID: 29694924
[TBL] [Abstract][Full Text] [Related]
17. Cardiolipin-deficient cells have decreased levels of the iron-sulfur biogenesis protein frataxin.
Li Y; Lou W; Grevel A; Böttinger L; Liang Z; Ji J; Patil VA; Liu J; Ye C; Hüttemann M; Becker T; Greenberg ML
J Biol Chem; 2020 Aug; 295(33):11928-11937. PubMed ID: 32636300
[TBL] [Abstract][Full Text] [Related]
18. N-oleoylethanolamide treatment of lymphoblasts deficient in Tafazzin improves cell growth and mitochondrial morphology and dynamics.
Chan JZ; Fernandes MF; Steckel KE; Bradley RM; Hashemi A; Groh MR; Sciaini G; Stark KD; Duncan RE
Sci Rep; 2022 Jun; 12(1):9466. PubMed ID: 35676289
[TBL] [Abstract][Full Text] [Related]
19. Cardiolipin metabolism and its causal role in the etiology of the inherited cardiomyopathy Barth syndrome.
Gaspard GJ; McMaster CR
Chem Phys Lipids; 2015 Dec; 193():1-10. PubMed ID: 26415690
[TBL] [Abstract][Full Text] [Related]
20. Restoration of mitophagy ameliorates cardiomyopathy in Barth syndrome.
Zhang J; Liu X; Nie J; Shi Y
Autophagy; 2022 Sep; 18(9):2134-2149. PubMed ID: 34985382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
